세계의 인공수정 시장 규모는 2023년 21억 달러에 달했습니다. 향후 IMARC Group은 시장이 2032년까지 42억 달러에 이를 전망이며 예측 기간 동안 7.5%의 복합 연간 성장률(CAGR)을 나타낼 것으로 예측했습니다. 불임률 증가, 라이프 스타일의 급속한 변화, 병리학의 만연이 시장을 견인하는 주요 요인 중 하나입니다.
인공수정은 의료 절차를 통해 정자를 여성의 생식 기관에 직접 넣는 수정 과정입니다. 일반적으로 신선한 정자 또는 냉동 정자를 사용하여 경관, 자궁, 질 등 다양한 방법으로 수행됩니다. 인공수정 구성 요소에는 정액 채취, 정액 처리 및 정액 설치가 포함됩니다. 인공수정은 임신 확률을 높이고 성병(STI)의 위험을 줄이고 남성 불임의 경우 기증자 정자를 사용할 수 있습니다. 또한 체외수정(IVF)(IVF)에 비해 인공수정은 낮은 침습(MI)으로 비용 효율적입니다. 현재 인공수정에는 주로 동종과 이종의 2유형가 있습니다. 동종 인공수정에서는 남성 파트너의 정자를 사용하여 여성 파트너의 난자를 수정시키지만, 이종 인공수정에서는 기증자 정자를 사용하여 여성 파트너의 난자를 수정시킵니다.
불임률 증가와 보조생식기술(ART)의 필요성은 시장 성장을 뒷받침하는 주요 요인 중 하나입니다. 라이프 스타일의 급속한 변화와 다낭성 난소 증후군(PCOS)과 자궁 내막증과 같은 병리학의 확산은 인공수정 수요를 급증시키고 시장 성장을 더욱 가속화하고 있습니다. 이는 신흥국에서의 인공수정의 수용과 이용 용이성의 향상에도 지지되고 있습니다. 또한 정자와 난자 선별, 동결보존, 착상전 유전자시험을 위한 개량기술의 개발 등 다양한 기술의 진보가 시장 성장을 가속하고 있습니다. 이 외에도 기증자 정자와 기증자 난자의 이용 가능성, 동성 결혼과 LGBT에 의한 육아의 인기가 높아지고, 의료 인프라의 개선 등도 시장 성장을 가속하는 요인으로 기대되고 있습니다. 게다가 유리한 규제의 존재, 불임증이나 인공수정에 대한 인식과 교육 캠페인 증가, 개별화,커스터마이즈형 인공수정 수요 증가 등이 시장 성장을 뒷받침하고 있습니다. 기타, 인공수정 서비스를 제공하는 클리닉이나 의료시설 증가, 인공수정처리에 보험이 적용되는 것, 출산을 지연시켜 경력목표를 추구하는 경향이 높아지고 있는 것 등이 시장 성장을 적극적으로 밀어주고 있습니다.
The global artificial insemination market size reached US$ 2.1 Billion in 2023. Looking forward, IMARC Group expects the market to reach US$ 4.2 Billion by 2032, exhibiting a growth rate (CAGR) of 7.5% during 2024-2032. Increasing infertility rates, rapid lifestyle changes, and escalating prevalence of medical conditions represent some of the key factors driving the market.
Artificial insemination is a process of fertilization that involves the placement of sperm directly into the female reproductive system through medical procedures. It typically involves the use of either fresh or frozen sperm and can be done in a variety of ways, including intracervical, intrauterine, or intravaginal methods. The components of artificial insemination include semen collection, semen processing, and semen placement. Artificial insemination offers increased chances of conception, reduced risk of sexually transmitted infections (STIs), and the ability to use donor sperm in cases of male infertility. Additionally, as compared to in vitro fertilization (IVF), artificial insemination is minimally invasive (MI) and cost-effective. Currently, there are two primary types of the procedure, including homologous and heterologous. Homologous insemination involves using the male partner's sperm to fertilize the female partner's egg, while heterologous insemination involves using donor sperm to fertilize the female partner's egg.
The increasing infertility rates and the need for assisted reproductive technologies (ART) are some of the key factors boosting the market growth. The rapid lifestyle changes and escalating prevalence of medical conditions, such as polycystic ovary syndrome (PCOS) and endometriosis, have surged the demand for artificial insemination procedures, further accelerating the market growth. This is further supported by the growing acceptance and accessibility of artificial insemination in emerging economies. Moreover, various technological advancements, such as the development of improved techniques for sperm and egg selection, cryopreservation, and pre-implantation genetic testing, are propelling the market growth. Besides this, the availability of donor sperm and donor eggs, the rising popularity of same-sex marriage and LGBT parenting, and the improving healthcare infrastructure are factors expected to drive the market growth. Furthermore, the presence of favorable regulations, the growing awareness and education campaigns about infertility and artificial insemination, and the escalating demand for personalized and customized artificial insemination procedures are fueling the market growth. Other factors, such as the increasing number of clinics and healthcare facilities offering artificial insemination services, the availability of insurance coverage for the procedure, and the surging trend of delaying childbirth and pursuing career goals, are positively supporting the market growth.
IMARC Group provides an analysis of the key trends in each sub-segment of the global artificial insemination market report, along with forecasts at the global, regional and country level from 2024-2032. Our report has categorized the market based on type, source type and end use.
Intrauterine
Intracervical
Intravaginal
Intratubal
The report has provided a detailed breakup and analysis of the global artificial insemination market based on the type. This includes intrauterine, intracervical, intravaginal, and intratubal. According to the report, the intrauterine segment dominates the market.
AIH-Husband
AID-Donor
The report has provided a detailed breakup and analysis of the global artificial insemination market based on the source type. This includes AIH-husband and AID-donor.
Hospitals and Clinics
Fertility Centers
Others
The report has provided a detailed breakup and analysis of the global artificial insemination market based on the end use. This includes hospitals and clinics, fertility centers, and others. According to the report, the fertility centers segment spearheads the market.
North America
United States
Canada
Asia-Pacific
China
Japan
India
South Korea
Australia
Indonesia
Others
Europe
Germany
France
United Kingdom
Italy
Spain
Russia
Others
Latin America
Brazil
Mexico
Others
Middle East and Africa
The report has also provided a comprehensive analysis of all the major regional markets, which include North America (the United States and Canada); Europe (Germany, France, the United Kingdom, Italy, Spain, Russia and others); Asia Pacific (China, Japan, India, South Korea, Australia, Indonesia, and others); Latin America (Brazil, Mexico, and others); and the Middle East and Africa. As per the report, North America dominates the market. Some of the factors accelerating the North America artificial insemination market include the surging awareness regarding the advantages of artificial insemination, the rising consumer per capita expenditure, and burgeoning healthcare expenditure.
The report has also provided a comprehensive analysis of the competitive landscape in the global artificial insemination market. Competitive analysis such as market structure, market share by key players, player positioning, top winning strategies, competitive dashboard, and company evaluation quadrant has been covered in the report. Also, detailed profiles of all major companies have been provided. Some of the companies covered include Conceivex Inc., FUJIFILM Irvine Scientific Inc. (Fujifilm Holdings Corporation), Genea Limited, Genus plc, Hamilton Thorne Inc., Hi-Tech Solutions, Kitazato Corporation, Pride Angel, Rinovum Women's Health LLC, Rocket Medical plc, TenderNeeds Fertility LLC, Vitrolife AB, etc. Kindly note that this only represents a partial list of companies, and the complete list has been provided in the report.